Search Results

Brazilian CancerThera Delegation Visits Uruguay's CUDIM to Advance Theranostics Cooperation in Oncology

Following the institutional partnership established between CEPID CancerThera and the Uruguayan Center for Molecular Imaging (CUDIM) in February this year, a Brazilian delegation visited Montevideo, Uruguay, from July 27 to 29 to advance the transformation of the memorandum of understanding into a concrete work plan. The visit focused on multicenter clinical trials, preclinical research, theranostics in oncology, and educational cooperation. During the visit, Brazilian researchers held working meetings with the CUDIM team, covering multiple aspects of oncology research development. CUDIM was represented by its General Director Alarico Rodriguez, as well as radiopharmacist and Technical Director of Radiopharmacy, Dr. Eduardo Osvaldo Savio Queve...

2026-08-20

Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Radiopharmaceutical Development for Solid Tumors

Akiram Therapeutics, a Swedish clinical-stage biotechnology company, and ITM Isotope Technologies Munich SE, a German radiopharmaceutical biotechnology company, recently announced the signing of a supply agreement. Under the agreement, ITM will supply no-carrier-added lutetium-177 (nca Lu-177) to Akiram to support the clinical development of its targeted antibody-radionuclide conjugate, 177Lu-AKIR001 (AKIR001). AKIR001 is Akiram's lead radiopharmaceutical candidate, currently being investigated in clinical studies for the treatment of CD44v6-expressing solid tumors. The candidate combines the therapeutic radioisotope nca Lu-177 with a proprietary antibody targeting CD44v6. CD...

2026-08-20

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Korean Research Team Reveals Mechanism Behind Neutron Irradiation-Induced Reliability Degradation in Ferroelectric AI Semiconductors

Jeonbuk National University announced on the 20th that a research team led by Professor Bae Hak-yeol from the Department of Electronic Engineering at its College of Engineering, in collaboration with Professor Kim Tae-wan's team at Seoul National University and Q-Beam Solution, a startup affiliated with the Korea Atomic Energy Research Institute, conducted a joint study analyzing the causes of performance degradation in next-generation ferroelectric memory and neuromorphic semiconductor devices under neutron irradiation. The findings have been published in the latest issue of ACS Applied Electronic Materials. Ferroelectric semiconductors, which can maintain their polarization state even after power is disconnected, are considered a key candidate for next-generation non-volatile memory and neuromorphic computing devices. Neuromorphic computing aims to simultaneously implement both memory and computation within a single device...

2026-08-20

CERN measures niobium-94 neutron capture for the first time, shedding new light on the mystery of molybdenum abundance in ancient stardust

The n_TOF collaboration at CERN recently reported that researchers have for the first time measured the probability of neutron capture by niobium-94. The results, published in Physical Review Letters, provide new experimental evidence for explaining the anomalous abundance of molybdenum-94 in presolar grains. The EAR2 facility in the n_TOF experiment at CERN produces intense neutron beams, opening new possibilities for nuclear research. Credit: CERN Niobium-94 is a niobium isotope containing 41 protons and 53 neutrons, occupying a critical juncture in the nuclear reaction chain that produces heavy elements in dying stars. Researchers are interested in it because niobium-94 is very close to molybdenum-94, differing by just one fewer proton and one more neutron. Under the high-temperature, high-pressure conditions inside stars, niobium-94 may either transform into molybdenum-94 through beta decay or form niobium-95 through neutron capture. The competition between these two reaction pathways directly affects scientists' understanding of the origin of molybdenum-94.

2026-08-20

Russian enterprise develops borated polyethylene material for neutron radiation protection

A neutron radiation protection material developed by Russian company NPO Gelar has obtained relevant certification. The material, named Polikeramoplast-PB, is a borated polyethylene that resembles ordinary gray or black plastic sheets in appearance, but its protective performance derives from the combination of hydrogen and boron. According to reports, the hydrogen in the material effectively moderates fast neutrons, reducing the likelihood of subsequent secondary reactions, while the boron helps absorb moderated neutrons. In contrast, traditional heavy metal materials used for gamma-ray shielding are not suitable for standalone neutron protection, as heavy atomic nuclei have limited attenuation effects on neutrons. The material can be used in radiation therapy room protection systems and combined with lead...

2026-08-19

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

NANO Nuclear and QNI Sign Memorandum of Understanding to Advance Domestic HALEU Fuel Supply Cooperation in the U.S.

NANO Nuclear Energy Inc. (NANO Nuclear) and Quadrant Nuclear Industries, Inc. (QNI) announced on August 18 that the two companies have signed a memorandum of understanding (MOU) establishing a non-binding framework for future high-assay low-enriched uranium (HALEU) fuel supply cooperation. Under the MOU, the parties will engage in discussions regarding the supply of HALEU to be produced by QNI in the future and long-term offtake arrangements. The fuel in question is planned to come from QNI's proposed Vanguard facility at Idaho National Laboratory (INL). QNI stated that once the facility operates at full capacity, its annual HALEU production...

2026-08-19

Russian Segment of ISS Adjusts BTN-M2 Equipment Configuration, Continues Neutron and Gamma Radiation Observations

On August 13, 2026, during the ISS-75 expedition mission, Russian cosmonauts Pyotr Dubrov and Anna Kikina performed configuration adjustments to the BTN-M2 scientific equipment inside the Nauka module of the Russian Segment of the International Space Station. Figure 1. Profiles of gamma rays (energies below 500 keV, black curve), 511 keV photons from electron-positron annihilation (green curve), and high-energy neutrons (red curve) detected by the BTN-M2 instrument aboard the ISS on July 30–31, 2026. Red arrows indicate enhanced gamma-ray flux during the solar proton event (SPE) as the ISS passed over high-latitude regions of the Earth...

2026-08-18

U.S. FRIB Secures Contract from Naval Nuclear Laboratory to Develop Quantum-Classical Hybrid Nuclear Reaction Calculation Methods

A research project at the Facility for Rare Isotope Beams (FRIB) at Michigan State University, led by Dean Lee, Professor of Physics at FRIB, Professor in the Department of Physics and Astronomy at Michigan State University, and Head of the Theoretical Nuclear Science Department at FRIB, has received one-year contract support from the Naval Nuclear Laboratory. The laboratory is managed by Fluor Marine Propulsion. The project will study how to combine quantum computers with classical computers to improve the accuracy of predictions for neutron interactions with matter. This also represents the first phase of a five-year plan aimed at developing and evaluating new computational tools for nuclear science. In nuclear physics research, accurately predicting how neutrons interact with atomic nuclei...

2026-08-18

Dongcheng Pharmaceutical Adds New Radiopharmaceutical Production Center in Jinzhong, Shanxi

Recently, Shanxi Andike, a subsidiary of Dongcheng Andike, which is a wholly-owned subsidiary of Dongcheng Pharmaceutical, received the "Radiopharmaceutical Production License" issued by the Shanxi Provincial Drug Administration. This marks that the Jinzhong Radiopharmaceutical Production Center in Shanxi has met the requirements for commissioning, adding a new facility to Dongcheng Pharmaceutical's radiopharmaceutical production network. As one of China's leading nuclear medicine companies, the group adheres to a layout strategy of "networked short half-life and base-based long half-life" production, and has established a domestically leading radiopharmaceutical production and distribution network. To date, the group has put 33 radiopharmaceutical production centers into operation. As a heparin expert and radiopharmaceutical pioneer, Dongcheng Pharmaceutical will continue to deepen its presence in the nuclear medicine field, striving to build a comprehensive Dongcheng nuclear medicine ecosystem...

2026-08-18

Decoding the Clinical-Radiological Paradox: Brain Network Mechanisms in Spinocerebellar Ataxia Type 3 Revealed

On August 17, the team of Professor Liu Chen and Professor Wang Jian from the Department of Radiology at Southwest Hospital of Army Medical University, in collaboration with Professor Long Zhiliang's team from the Faculty of Psychology at Southwest University, systematically revealed for the first time the micro-level molecular pathological mechanisms underlying macroscopic brain network decoupling in patients with spinocerebellar ataxia type 3 (SCA3) by integrating multimodal magnetic resonance imaging technology with high-resolution micro-biological atlases. This provides a novel perspective and objective imaging targets for resolving the clinical-radiological dissociation challenge in clinical diagnosis and treatment. The findings were published in the internationally leading journal in the field of movement disorders under the title "Putaminal Structure-Function Decoupling as an Early Candidate Imaging Biomarker for Motor Severity in Spinocerebellar Ataxia Type 3."

2026-08-18

First American Nuclear Company's Regulatory Engagement Plan for Proposed HALEU Fuel Facility Accepted for Docketing by NRC

First American Nuclear Co. (FANCO) announced on August 17 that its regulatory engagement plan for the proposed Class II high-assay low-enriched uranium (HALEU) conversion and fuel fabrication facility has been accepted for docketing by the U.S. Nuclear Regulatory Commission (NRC). The facility will serve the company's EAGL-1 small modular reactor project currently under development. According to the company's disclosure, the NRC ADAMS accession number for the letter of intent is ML26222A181, and the NRC ADAMS accession number for the regulatory engagement plan is ML26222A177. This submission advances the pre-application regulatory engagement between FANCO and the NRC regarding the proposed ceramic fuel fabrication facility. The facility is planned to support the EAGL-1 lead-bismuth...

2026-08-18

Neutron and X-ray tomography reveal hydrogen-rich regions in Martian meteorite "Black Beauty"

An international team of researchers from Denmark, Sweden, and Switzerland recently conducted a three-dimensional non-destructive analysis of a slice of the Martian meteorite NWA 7034 "Black Beauty" using neutron tomography and X-ray tomography, discovering macroscopic hydrogen-rich regions within it. The study suggests that these hydrogen-rich features provide evidence of early water-rock interactions on Mars. The findings have been published in Geophysical Research Letters. Black Beauty is a brecciated meteorite from Mars that was ejected into space by an impact event and eventually landed in the Sahara Desert in Morocco. Weighing approximately 320 grams, the meteorite contains material up to 4.48 billion years old, making it one of the oldest known Martian crustal fragments...

2026-08-17

South Korea's domestically developed lunar radiation detector to travel to the Moon aboard NASA commercial lunar lander

The Korea AeroSpace Administration (KASA) announced on August 17 that the Lunar Space Radiation Detector (LVRAD), independently developed by South Korea, will be mounted on a lander under NASA's Commercial Lunar Payload Services (CLPS) program to conduct observations of the radiation environment on the lunar south pole surface. The two sides signed the relevant implementation agreement on August 14. Under the agreement, KASA plans to complete the development of the flight model of the detector by next year and deliver the equipment to the United States in accordance with the NASA lunar lander mission schedule. NASA will be responsible for integrating the Korean-developed detector onto the commercial lunar lander and supporting its operation and data transmission on the lunar surface after launch. LVRAD consists of...

2026-08-17